Cat. No.: HY-137977

DMU-212

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

DMU-212 is a methylated derivative of Resveratrol (HY-16561), with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of ERK1/2 protein. DMU-212 has orally active.

For research use only. We do not sell to patients.

Purity: 99.31%
CAS No.: 134029-62-2
Formula: C₁₈H₂₀O₄
Molecular Weight:300.35

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

DMU-212 Chemical Structure

CAS No.: 134029-62-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All ERK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	5.42 μM Compound: DMU-212	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
A498	GI₅₀	0.74 μM Compound: DMU-212	Growth inhibition of human A498 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
A549	ED₅₀	1.18 μM Compound: 6a	Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines	[PMID: 1875350]
A549	GI₅₀	3.7 μM Compound: DMU-212	Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
ACHN	GI₅₀	4.51 μM Compound: DMU-212	Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
CAKI-1	GI₅₀	3 μM Compound: DMU-212	Growth inhibition of human Caki1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human Caki1 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
CCRF-CEM	GI₅₀	2.89 μM Compound: DMU-212	Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
COLO 205	GI₅₀	2.07 μM Compound: DMU-212	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
DU-145	GI₅₀	4.23 μM Compound: DMU-212	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
HCC 2998	GI₅₀	3.59 μM Compound: DMU-212	Growth inhibition of human HCC2998 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
HCT-116	GI₅₀	3.23 μM Compound: DMU-212	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
HCT-116	IC₅₀	0.53 μM Compound: 10E	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21215623]
HCT-116	IC₅₀	1.1 μM Compound: DMU-212	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition Anticancer activity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 32485531]
HCT-15	GI₅₀	2.82 μM Compound: DMU-212	Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
HepG2	IC₅₀	0.3 μM Compound: 1, DMU- 212	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 21497957]
HL-60(TB)	GI₅₀	3.14 μM Compound: DMU-212	Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
HOP-62	GI₅₀	3.14 μM Compound: DMU-212	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
HOP-92	GI₅₀	7.23 μM Compound: DMU-212	Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
Hs-578T	GI₅₀	3.09 μM Compound: DMU-212	Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
HT-29	ED₅₀	1.82 μM Compound: 6a	Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines	[PMID: 1875350]
HT-29	GI₅₀	2.32 μM Compound: DMU-212	Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
IGROV-1	GI₅₀	5.29 μM Compound: DMU-212	Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
IMR-90	IC₅₀	0.16 μM Compound: 10E	Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay	[PMID: 21215623]
KM12	GI₅₀	3.63 μM Compound: DMU-212	Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
LOX IMVI	GI₅₀	4.89 μM Compound: DMU-212	Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
M14	GI₅₀	2.81 μM Compound: DMU-212	Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
MCF7	ED₅₀	1.05 μM Compound: 6a	Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines	[PMID: 1875350]
MCF7	GI₅₀	1.66 μM Compound: DMU-212	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
MCF7	IC₅₀	0.22 μM Compound: 10E	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 21215623]
MCF7	IC₅₀	0.3 μM Compound: 1, DMU- 212	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 21497957]
MCF7	IC₅₀	4.8 nM Compound: Table 1, R13C1	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19135763]
MDA-MB-231	GI₅₀	3.74 μM Compound: DMU-212	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
MDA-MB-435	GI₅₀	1.04 μM Compound: DMU-212	Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
MDA-MB-468	GI₅₀	2.22 μM Compound: DMU-212	Growth inhibition of human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
MLM	ED₅₀	2.07 μM Compound: 6a	Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines	[PMID: 1875350]
MOLT-4	GI₅₀	3.22 μM Compound: DMU-212	Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
NCI/ADR-RES	GI₅₀	3.01 μM Compound: DMU-212	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
NCI-H23	GI₅₀	3.37 μM Compound: DMU-212	Growth inhibition of human NCI-H23 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
NCI-H522	GI₅₀	3.7 μM Compound: DMU-212	Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
OVCAR-3	GI₅₀	3.45 μM Compound: DMU-212	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
OVCAR-4	GI₅₀	4 μM Compound: DMU-212	Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
PC-3	GI₅₀	3.22 μM Compound: DMU-212	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
RPMI-8226	GI₅₀	6.42 μM Compound: DMU-212	Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SF-268	GI₅₀	7.59 μM Compound: DMU-212	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SF-295	GI₅₀	2.18 μM Compound: DMU-212	Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SF-539	GI₅₀	2.18 μM Compound: DMU-212	Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SK-MEL-2	GI₅₀	3.95 μM Compound: DMU-212	Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SK-MEL-28	GI₅₀	3.86 μM Compound: DMU-212	Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SK-MEL-5	ED₅₀	0.81 μM Compound: 6a	Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines	[PMID: 1875350]
SK-MEL-5	GI₅₀	2.5 μM Compound: DMU-212	Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SK-OV-3	GI₅₀	3.34 μM Compound: DMU-212	Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SNB-19	GI₅₀	4.85 μM Compound: DMU-212	Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SNB-75	GI₅₀	1.88 μM Compound: DMU-212	Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SR	GI₅₀	3.93 μM Compound: DMU-212	Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
SW-620	GI₅₀	2.07 μM Compound: DMU-212	Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
U-251	GI₅₀	3.07 μM Compound: DMU-212	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
UACC-62	GI₅₀	2.37 μM Compound: DMU-212	Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]
UO-31	GI₅₀	3.69 μM Compound: DMU-212	Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay	[PMID: 27017113]

In Vitro

DMU-212 (0.3125-40 μM) inhibits growth of A375, MeWo, Bro and M5 human melanoma cells^[1].
DMU-212 (30-50 μM; 24 hours) induces upregulation of cell cycle inhibitors, apoptosis and ERK activation in A375 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

A375 cells, MeWo cells, M5 cells, Bro cells
Concentration:

0.3125 μM, 0,625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

96 hours
Result:

Inhibited the cellular proliferation of human melanoma cells at submicromolar or micromolar concentrations (IC₅₀=0.5 μM for A375 and Bro and IC₅₀= 1.25 μM for MeWo and M5 cells).

Cell Cycle Analysis^[1]

Cell Line:

A375 cells
Concentration:

20 μM, 30 μM, 50 μM
Incubation Time:

24 hours
Result:

Caused a marked increase in the levels of p21, p53 and cyclin B1 proteins with a concomitant decrease in the levels of cyclin A2.

Western Blot Analysis^[1]

Cell Line:

A375 cells
Concentration:

20 μM, 30 μM, 50 μM
Incubation Time:

24 hours
Result:

Significant upregulated Bax, caspase 3 and caspase 9 protein levels, while decreased the levels of the anti-apoptotic protein Bcl-2.

Apoptosis Analysis^[1]

Cell Line:

A375 cells
Concentration:

10 μM, 20 μM
Incubation Time:

24 hours, 36 hours
Result:

Induced apoptosis.

In Vivo

DMU-212 (50 mg/kg; i.g.; three times a week; for 14 days) inhibits tumor growth in xenograft model of human ovarian cancer^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6-weeks-old SCID female mice (20-24 g), with ovarian cancer xenografts^[2]
Dosage:

50 mg/kg
Administration:

Oral gavage, three times a week, for 14 days
Result:

Lowered tumor burden.

Chemical Information

CAS No. 134029-62-2
Appearance Solid
Molecular Weight 300.35
Formula C₁₈H₂₀O₄
Color White to off-white
SMILES

COC1=CC=C(/C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Nat Commun

Engineered model of heart tissue repair for exploring fibrotic processes and therapeutic interventions. [Abstract]

2024 Sep 12;15(1):7996. PMID: 39266508
J Neurosci

GRM2 Regulates Functional Integration of Adult-Born DGCs by Paradoxically Modulating MEK/ERK1/2 Pathway. [Abstract]

2023 Apr 19;43(16):2822-2836. PMID: 36878727

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL (66.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3294 mL

16.6472 mL

33.2945 mL

5 mM

0.6659 mL

3.3294 mL

6.6589 mL

10 mM

0.3329 mL

1.6647 mL

3.3294 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2 mg/mL (6.66 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Vasilis Pericles Androutsopoulos, et al. Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4'-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 2015 Aug;24(8):632-4. [Content Brief]

[2]. Hanna Piotrowska, et al. DMU-212 inhibits tumor growth in xenograft model of human ovarian cancer. Biomed Pharmacother. 2014 May;68(4):397-400. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3294 mL	16.6472 mL	33.2945 mL	83.2362 mL
	5 mM	0.6659 mL	3.3294 mL	6.6589 mL	16.6472 mL
	10 mM	0.3329 mL	1.6647 mL	3.3294 mL	8.3236 mL
	15 mM	0.2220 mL	1.1098 mL	2.2196 mL	5.5491 mL
	20 mM	0.1665 mL	0.8324 mL	1.6647 mL	4.1618 mL
	25 mM	0.1332 mL	0.6659 mL	1.3318 mL	3.3294 mL
	30 mM	0.1110 mL	0.5549 mL	1.1098 mL	2.7745 mL
	40 mM	0.0832 mL	0.4162 mL	0.8324 mL	2.0809 mL
	50 mM	0.0666 mL	0.3329 mL	0.6659 mL	1.6647 mL
	60 mM	0.0555 mL	0.2775 mL	0.5549 mL	1.3873 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

DMU-212

Antioxidant Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) DMU-212

All ERK Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

DMU-212

Antioxidant Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) DMU-212

All ERK Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

DMU-212 Related Classifications

HY-137977 Related Classifications